Bimatoprost Lower Intraocular Pressure and Increases Eyelash Growth

Bimatoprost Lower Intraocular Pressure and Increases Eyelash Growth

Bimatoprost Lower Intraocular Pressure and Increases Eyelash Growth
Drug Research & Development API, OTC and Compounding Product, Prostaglandin


Bimatoprost, CAS #155206-00-1 opthamolic solution has been known for being effectual at lowering intraocular pressure in adult patients. A new benefit of Bimatoprost has stolen the pharmaceutical headlines, however, with the advent of Latisse, for treating hypotrichosis of the eyelashes. Touted by long time movie star and model Brooke Shields, Latisse is recommended for people who wish to increase their growth, length, darkness and thickness of their eyelashes. This 0.03% solution of Allergan’s Bimatoprost has proven in a plethora of studies to be effective and safe for patients who use this therapy for hypotrichosis of the eyelashes, as well as elevated intraocular pressure.

Patients who are utilizing Bimatoprost for increased eyelash growth utilize this therapy by applying one full sterile applicator of this solution to the skin of their upper eyelid, specifically at the base of the eyelashes. As a viable prostaglandin analog Latisse (Bimatoprost 0.03% opthamolic solution) has not caused serious adverse side effects. A minority of patients have complained of a darkened brown area of their iris developing, particularly for people who have hazel eyes. The upside of this product is the ability for patients to access it via medical spas and coordinate their treatments alongside other beauty regimens, such as Botox. Success is an understatement when referring to Bimatoprost as an eyelash enhancer product. Last year 74 million dollars of Latisse was sold, and figures are expected to double in 2015. Net sales overall are projected by pharmaceutical analysts to ultimately exceed 500 million dollars annually if patients end up being able to access this treatment without a prescription.

Bimatoprost is also known as the brand name eye drop Lumigan, which is also marketed by Allergan for decreasing intraocular eye pressure in patients at risk of getting glaucoma. LGM Pharma can assist clients as a supplier/distributor of the API Bimatoprost, CAS #155206-00-1 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service